Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Milestone Pharmaceuticals (Nasdaq: MIST) granted a total of 123,000 stock options under its 2021 Inducement Plan as material inducements for three new hires.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Milestone Pharmaceuticals (Nasdaq: MIST) granted a total of 123,000 stock options under its 2021 Inducement Plan as material inducements for three new hires. The options were granted with an April 1, 2026 grant date and an exercise price of $1.31, equal to the closing share price on that date. The options vest over four years (25% after one year, then monthly over 36 months) and are subject to continuous service and the Plan's terms pursuant to Nasdaq Listing Rule 5635(c)(4).
Details
News Market Reaction – MIST
On Apr 2, the day this news came out, MIST closed 5.34% above the previous close.
Data tracked by StockTitan Argus for the Apr 2 session.
Key Figures
- Inducement options granted
- 123,000 options
- Granted under 2021 Inducement Plan to three new employees
- Exercise price
- $1.31 per share
- Equal to closing price on April 1, 2026 grant date
- New hires
- 3 employees
- Options granted as material inducement to hiring
- Vesting duration
- 4 years
- Options vest over four years subject to continuous service
- Initial vesting tranche
- 25%
- Vests on the one-year anniversary of vesting commencement date
- Remaining installments
- 36 monthly installments
- Balance vests in 36 successive equal monthly installments
Historical Context
-
CARDAMYST added to Express Scripts commercial national formularies, broadening access.
-
Reported CARDAMYST approval, U.S. launch and liquidity runway alongside 2025 results.
-
ACC.26 data showing minimal blood pressure effects and low hypotension/syncope rates.
-
Announcement of date and access details for Q4 and full-year 2025 results call.
-
Planned presentation at TD Cowen health care conference with webcast access.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
equity awards financial
stock options financial
inducement plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
MONTREAL and CHARLOTTE, N.C., April 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 123,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to the hiring of three new employees.
The Options have a grant date of April 1, 2026, and an exercise price of
The Option awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of the Plan and its standard forms of grant agreements thereunder.
The foregoing equity award was granted as an inducement material to the employees entering into employment with Milestone, in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Milestone, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Milestone, pursuant to Nasdaq Listing Rule 5635(c)(4).
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the treatment of symptomatic episodic attacks associated with AFib-RVR.
Contact:
Kevin Gardner kgardner@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.